5.74
-3.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Myriad Genetics
From its filings with the US Securities and Exchange Commission
Myriad Genetics is based in Salt Lake City, Utah and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MYGN. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2025, it reported revenue of $824.5m and a net loss of $365.9m. At that date it held total assets of $706.6m and shareholders' equity of $368.0m. By business, Hereditary Cancer brought in 45.2% of revenue, followed by Prenatal at 22.6% and Mental Health at 17.5%. By region, U.S. accounted for 93.1%, followed by RoW at 6.9%.
Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care. We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission. We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services.
Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine. Our strategy also leverages investments in science and innovation, technology-enabled operations, an enhanced customer experience, strong commercial execution, and scalable operations. Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum (CCC) market with a priority for high growth applications; (ii) growing our Prenatal Health and Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Oct 1995
- Employees
- 2,700
- Website
- myriad.com ↗
- Head office
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Incorporated in
- DE
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Ms. S. Louise PhanstielIndependent Chairman of the Board$563,499
- Mr. Samraat RahaPresident, Chief Executive Officer, Director, since 2023$4.4m
- Mr. Benjamin WheelerChief Financial Officer
- Mr. Mark VerrattiChief Operating Officer and Chief Commercial Officer$3.7m
- Ms. Shereen SolaimanChief People Officer
- Ms. Margaret AnconaSenior Vice President, Chief of Staff
- Mr. Kevin HaasChief Technology Officer$1.6m
- Dr. Dale MuzzeyChief Scientific Officer$3.0m
- Mr. Brian DonnellyChief Commercial Officer
- Ms. Jennifer FoxChief Legal Officer
- Mr. Paul BisaroIndependent Director$449,345
- Mr. Mark DavisIndependent Director$349,997
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 36
- Social
- 51
- Governance
- 37
- Women in the workforce
- 61%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Intellectual Property Portfolio: Myriad Genetics Inc possesses a significant number of patents and licenses, providing a competitive advantage in the genetic testing industry.
- Broad Range of Products and Services: The company offers a comprehensive suite of genetic tests and related services, catering to different medical specialties and patient needs.
- Established Market Presence: Myriad Genetics Inc has achieved a reputable position in the market, with a long history of delivering reliable genetic testing solutions and gaining the trust of healthcare professionals.
Weaknesses
- Dependence on Few Key Products: Myriad Genetics Inc relies heavily on a limited number of flagship products, which exposes the company to the risk of market fluctuations and potential loss of market share.
- Regulatory Challenges: The genetic testing industry is tightly regulated, and changing regulations can impact Myriad Genetics Inc's ability to operate or require costly compliance measures.
- Limited International Expansion: The company's presence is primarily concentrated in the United States, limiting its potential growth opportunities in international markets.
Opportunities
- Growing Demand for Genetic Testing: The increasing awareness and importance of personalized medicine present a significant opportunity for Myriad Genetics Inc to expand its customer base and introduce new testing solutions.
- Advances in Genetic Research: Technological advancements and ongoing research in genetics offer the potential for the development of innovative tests and services, allowing the company to stay ahead of competitors.
- Strategic Partnerships: Collaborating with pharmaceutical companies, healthcare organizations, and research institutions can provide Myriad Genetics Inc with access to new markets, resources, and expertise.
Threats
- Competition: The genetic testing industry is becoming increasingly competitive, with the entry of new players and the presence of established companies offering similar services, posing a threat to Myriad Genetics Inc's market share.
- Reimbursement Challenges: Changes in healthcare policies and reimbursement rates can impact the company's profitability and restrict patient access to genetic testing services.
- Ethical and Legal Concerns: The handling and interpretation of genetic data raise ethical and privacy concerns, requiring Myriad Genetics Inc to continually address legal and regulatory challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.